Flamingo-01 Phase III GP2 Product Press Releases Email Alerts

ABOUT
- MANAGEMENT TEAM
- BOARD OF DIRECTORS
TECHNOLOGY
- OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
- CANCER AND IMMUNOTHERAPY OVERVIEW
CLINICAL TRIALS
- COMPLETED PHASE IIB CLINICAL TRIAL
- FLAMINGO-01 PHASE III CLINICAL TRIAL
INVESTORS & MEDIA
CONTACT

ABOUT
- MANAGEMENT TEAM
- BOARD OF DIRECTORS
TECHNOLOGY
- OUR GP2 CANCER IMMUNOTHERAPY PRODUCT
- CANCER AND IMMUNOTHERAPY OVERVIEW
CLINICAL TRIALS
- COMPLETED PHASE IIB CLINICAL TRIAL
- FLAMINGO-01 PHASE III CLINICAL TRIAL
INVESTORS & MEDIA
CONTACT

Presentations

Investors

Overview
News & Events
Company Info
- Presentations
- FAQ
Stock Info
SEC Filings
Governance

Company Info
Presentations
FAQ

Corporate Presentation - September 2022 (PDF)

Sep 21, 2022

Corporate Presentation - September 2022 (PDF)

Corporate Presentation - November 2021 (Webcast)

Nov 9, 2021

Corporate Presentation - November 2021 (Webcast)

By proceeding to use this website, you consent to our use of cookies as described in our Privacy Policy.

Email Alerts

Sign up Now

We're sorry, but this form has spam protection that requires JavaScript to be enabled to work correctly. If you'd like to contact us via this form, please enable scripts in your browser and reload the page.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

All Press Releases

All SEC Filings

10-K & 10-Q Reports

Current Reports

Insider Transactions

Proxy Information

Tear Sheet
RSS Feed

Copyright © 2023

Greenwich LifeSciences, Inc.

CLINICAL TRIALS

INVESTORS & MEDIA

Copyright © 2023

Greenwich LifeSciences, Inc.

CLINICAL TRIALS

INVESTORS & MEDIA